Faron Pharmaceuticals Oy (DI) (FARN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

170.00p
   
  • Change Today:
      5.00p
  • 52 Week High: 262.50
  • 52 Week Low: 150.00
  • Currency: UK Pounds
  • Shares Issued: 114.42m
  • Volume: 5,355
  • Market Cap: £194.51m
  • Beta: 0.22

FARN Overview

We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.

1 Day Chart (22-12-2025)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a -185.4%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a 15.4
Pr/Book n/a  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

FARN Fundamentals

Year Ending Revenue ( m) Pre-tax ( m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 n/a (16.93) (37.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (21.18) (42.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (28.73) (52.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (30.94) (48.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-24 n/a (25.92) (29.00)¢ n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

FARN Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 12.67 (23.48) (15.41)p n/a n/a n/a n/a 0.0%
31-Dec-26 n/a (32.05) (25.74)p n/a n/a n/a n/a 0.0%
31-Dec-27 27.37 (18.40) (20.57)p n/a n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

FARN Company Announcements

FDA Grants Orphan Drug Designation 03-Mar-2025 12:05 RNS
Notice of Annual General Meeting 28-Feb-2025 12:00 RNS
Positive EMA Opinion on Orphan Drug Designation 27-Feb-2025 07:30 RNS

FARN ShareCast News

Faron issuing second tranche of unsecured conver... 11-Dec-2025 ShareCast
Faron Pharmaceuticals appoints new finance chief 01-Dec-2025 ShareCast
Faron strengthens bexmarilimab potential with fr... 20-Oct-2025 ShareCast

Latest FARN Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

FARN Market Data

Currency UK Pounds
Share Price 170.00p
Change Today 5.00p
% Change 3.03 %
52 Week High 262.50
52 Week Low 150.00
Volume 5,355
Shares Issued 114.42m
Market Cap £194.51m
Beta 0.22

FARN Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
41.46% below the sector average41.46% below the sector average41.46% below the sector average41.46% below the sector average41.46% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average54.55% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 0
Sell 0
Strong Sell 1
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

FARN Dividends

No dividends found

Trades for 22-Dec-2025

Time Volume / Share Price
15:22 406 @ 172.00p
15:01 289 @ 172.13p
11:36 2,000 @ 173.40p
10:08 1,500 @ 173.50p
09:41 300 @ 173.50p

FARN Key Personnel

CEO Juho Jalkanen
Chair Tuomo Pätsi
CFO Jurriaan Dekkers

Top of Page